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ABSTRACT
Lactoferrin and lysozyme are 2 glycoproteins with 
great antimicrobial activity, being part of the nonspe-
cific defensive system of human milk, though their use 
in commercial products is difficult because human milk 
is a limited source. Therefore, many investigations have 
been carried out to produce those proteins in biological 
systems, such as bacteria, yeasts, or plants. Mammals 
seem to be more suitable as expression systems for 
human proteins, however, especially for those that are 
glycosylated. In the present study, we developed a bi-
cistronic commercial vector containing a goat β-casein 
promoter and an internal ribosome entry site fragment 
between the human lactoferrin and human lysozyme 
genes to allow the introduction of both genes into bo-
vine adult fibroblasts in a single transfection. Embryos 
were obtained by somatic cell nuclear transfer, and, 
after 6 transferences to recipients, 3 pregnancies and 1 
viable bitransgenic calf were obtained. The presence of 
the vector was confirmed by fluorescent in situ hybrid-
ization of skin cells. At 13 mo of life and after artificial 
induction of lactation, both recombinant proteins were 
found in the colostrum and milk of the bitransgenic 
calf. Human lactoferrin concentration in the colostrum 
was 0.0098 mg/mL and that in milk was 0.011 mg/mL; 
human lysozyme concentration in the colostrum was 
0.0022 mg/mL and that in milk was 0.0024 mg/mL. The 
molar concentration of both human proteins revealed 
no differences in protein production of the internal ri-
bosome entry site upstream and downstream protein. 
The enzymatic activity of lysozyme in the transgenic 
milk was comparable to that of human milk, being 6 
and 10 times higher than that of bovine lysozyme pres-
ent in milk. This work represents an important step to 
obtain multiple proteins or enhance single protein pro-
duction by using animal pharming and fewer regulatory 
and antibiotic-resistant foreign sequences, allowing the 
design of humanized milk with added biological value 
for newborn nutrition and development. Transgenic 
animals can offer a unique opportunity to the dairy in-
dustry, providing starting materials suitable to develop 
specific products with high added value.
Key words: bitransgenic cow, human lactoferrin, 
ELISA, human lysozyme
INTRODUCTION
Breast milk provides not only nutrients to a newborn, 
but also bioactive components for the development of 
tissues and physiological functions (Pereira, 2014). In 
some cases breastfeeding must be substituted with 
formula milk that is mainly derived from bovine milk; 
however, several studies have shown that breastfed ba-
bies have fewer infections than those fed infant formula 
(O’Connor and Unger, 2013). Bovine milk has a higher 
content of total protein than human milk, but some of 
the proteins of the human secretion are not present, 
or are at lower levels, in bovine milk. Among those 
at lower levels, lactoferrin and lysozyme are proteins 
that provide strong defense to newborn due to their 
antimicrobial activity against a broad spectrum of bac-
teria, viruses, yeasts, fungi, and parasites (Farnaud and 
Evans, 2003; Bayarri et al., 2014). Lactoferrin is the 
major antimicrobial protein in the milk of most mam-
mals; it is a glycoprotein of approximately 80 kDa that 
belongs to the family of iron-binding proteins called 
transferrins (González-Chávez et al., 2009). Lactofer-
rin is synthesized by the epithelial cells of the external 
mucous membranes, present also in some bodily fluids, 
such as tears and saliva, although the highest levels are 
detected in milk secretions (Farnaud and Evans, 2003). 
However, the amount of lactoferrin is quite different 
between human and bovine milk; in human colostrum 
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the concentration is about 6 mg/mL, whereas in bovine 
colostrum it is around 1 mg/mL (Sánchez et al., 1988; 
Montagne et al., 2001). In both species, the concentra-
tion of lactoferrin decreases dramatically in the first 
days of lactation, remaining around 2 and 0.1 mg/mL 
in human and bovine mature milks, respectively (Sán-
chez et al., 1988; Montagne et al., 2001).
Lysozyme is an enzyme of about 14 kDa consisting of 
a polypeptide chain of 130 AA. It is widely distributed 
in body fluids such as tears, saliva, blood, and other 
secretions, playing an important role in the nonspecific 
defenses of the individual (Zhou et al., 2014). Lysozyme 
is a hydrolase enzyme able to damage the bacterial 
cells by breaking the β-(1–4)-glycosidic bond between 
N-acetylglucosamine and N-acetylmuramic acid of the 
peptidoglycan chain present in the cellular bacterial 
wall (Niyonsaba and Ogawa, 2005). In human milk the 
lysozyme concentration is about 0.37 and 0.24 mg/mL 
in colostrum and mature milk, respectively (Montagne 
et al., 2001), whereas in bovine milk its concentration 
is practically undetectable, about 10 ng/mL (Król et 
al., 2010).
Transgenic animals can be used for several purposes: 
they have been used as animal models of human disease 
to find new treatments (Duverger et al., 1996; Carter, 
2004), as sources of organs for xenotransplantation 
(Houdebine, 2000; Niemann, 2001), for the study of 
gene expression, promoter regulation, and codifying 
sequences (Montoliu, 2002; Giraldo et al., 2003), and as 
“biofactories” to produce human therapeutic proteins 
for pharmaceutical or nutraceutical purposes. The com-
position of an animal product, such as milk or meat, 
can be altered to make a functional food (Brem et al., 
1994; Houdebine, 1994; Limonta et al., 1995; Hwang 
et al., 2004) with enhanced functionality due to mam-
malian post-translational modification of recombinant 
proteins. Considering that the availability of human 
milk-derived natural proteins, such as human lactofer-
rin and human lysozyme, is limited, alternative ways 
of production for these biopharmaceutical products are 
being extensively researched (Maga et al., 2006; Zhang 
et al., 2008; Goldman et al., 2012; Meng et al., 2013).
Multitransgenic animals have been obtained by using 
reproductive and molecular biotechnologies (Webster 
et al., 2005; Deng et al., 2011). The method to obtain 
multitransgenic animals for medical and veterinary pur-
poses should be simple and efficient so that it allows for 
simultaneously modifying certain traits or enhancing 
the production of a certain protein by the inclusion of 
multiple copies of the same gene in the vector construc-
tion. Different strategies, such as mating transgenic 
pigs obtained for the production of single recombinant 
proteins, have been used to achieve this in pigs (Zhou 
et al., 2005). However, in addition to the low efficiency 
of the principal techniques to obtain transgenic ani-
mals (pronuclear microinjection, viral vectors, sperm-
mediated gene transfer, nuclear transfer), these proto-
cols include time-consuming and expensive breeding 
programs (Niemann and Kues, 2003). One of the most 
questionable aspects of the use of more than one vector 
for obtaining multitransgenic animals is the presence of 
different markers that are constitutively expressed and 
multiple viral or bacterial sequences for each transgenic 
process. Moreover, as we found in previous experiments, 
repeated transfection rounds of a single cell line render 
the line unviable for nuclear transfer procedures; cells 
grew in a different way, adopting globose shape, and we 
could not obtain embryos after the cloning procedure. 
Moreover, the use of heterologous promoters sometimes 
generates promoter interference; that is, transcription 
from one promoter suppresses transcription from an-
other (Shearwin et al., 2005; Blazeck and Alper, 2013).
Internal ribosome entry sites (IRES) have been pro-
posed to express 2 distinct coding sequences under the 
control of only 1 promoter, which is of great interest to 
molecular and cellular biologists. Unlike that observed 
in most eukaryotic mRNA, in which ribosomes scan 
from the 5′ end until the initiation codon is reached, 
in mRNA of picornaviruses (Jackson et al., 1990), such 
as encephalomyocarditis virus, ribosomes are able to 
begin translation at IRES. These IRES elements can 
be removed from their viral setting and linked to un-
related genes to produce polycistronic RNA (Gurtu et 
al., 1996). We hypothesized that IRES sequences in-
serted in a vector with a tissue-specific promoter may 
allow the expression of 2 human proteins from only 1 
mRNA (bicistronic expression) in the cattle mammary 
gland, avoiding the successive transfections and mul-
tiple antibiotic insertions into donor cells before nuclear 
transfer. Thus, the objective of our work was to assess 
the feasibility of introducing, in a single transfection, a 
bicistronic vector containing an IRES fragment with 2 
human genes (lactoferrin and lysozyme) in a bovine cell 
culture, and to obtain embryos by somatic cell nuclear 
transfer (SCNT), pregnancies, and the birth of double 
transgenic individuals able to express the human pro-
teins in the mammary gland.
MATERIALS AND METHODS
Generation of Transgenic Cow
Ethics Statement. Because the expected births 
were genetically modified organisms, the facilities used 
for this experiment were designed to achieve resolution 
number 443/12 of the Ministerio de Agricultura, Ga-
nadería y Pesca de la Nación (Argentina). This work was 
carried out after its approval by the National Commis-
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sion of Agricultural Biotechnology (CONABIA, Buenos 
Aires, Argentina), presentation # S01:0325784/2011.
All procedures performed with animals were in ac-
cordance with the ethical standards of the Instituto 
Nacional de Tecnología Agropecuaria (Balcarce, Ar-
gentina) and Universidad Nacional de San Martin (San 
Martin, Argentina), where the studies were conducted. 
The procedures for animal care and methods of sacri-
fice were approved by the CICUAE (for Internal Com-
mission for Experimental Animal Care, in Spanish) of 
the Veterinary Council (National Universities, Buenos 
Aires, Argentina), resolution 011/2011. The health of 
all bovine individuals used or obtained in this work was 
controlled by veterinarians.
The raw human milk samples used for lactoferrin iso-
lation were donated by the human milk bank of Zara-
goza (Spain). The study was approved by the Ethical 
Committee for Clinical Research of the Government of 
Aragón (Zaragoza, Spain) and informed consent was 
obtained from all donors.
Chemicals and Reagents. Unless otherwise indi-
cated, all chemicals and reagents were purchased from 
Sigma-Aldrich (St. Louis, MO).
Construction of Expression Vectors. A 1,960-bp 
cDNA (GenBank accession number NM_002343) ob-
tained from American Type Culture Collection encom-
passing the entire coding region of human lactoferrin 
was used. The gene was amplified from the original 
vector by PCR and cloned in the pGEM-T easy vec-
tor (Promega, Madison, WI). Primers contained the 
recognition sequence for XhoI (New England Biolabs, 
Ipswich, MA) in their extremes.
Human lysozyme cDNA was obtained by reverse-
transcription PCR using as a template mRNA of an 
in vitro macrophage culture obtained from peripheral 
blood. The 438-bp fragment corresponding to the com-
plete codifying sequence of the gene was cloned in the 
pGEM-T vector, but primers had different restriction 
sequences, specifically MscI (forward) and EagI (re-
verse; New England Biolabs).
The pIRES2-EGFP vector (Clontech Inc., Mountain 
View, CA) was used to construct the mammary gland 
expression vector. The cytomegalovirus promoter was 
replaced by the goat β-CN obtained from the pBC-
1 milk expression system (Invitrogen, Carlsbad, CA), 
by PCR with Platinum TAQ DNApol (Gibco, Thermo 
Fisher Scientific, Waltham, MA), and a primer con-
taining restriction sequences Asel (forward) and Nhel 
(reverse; New England Biolabs). The Kozak sequence 
was added to each oligonucleotide used to amplify the 
human genes to achieve better ribosomal recognition 
and their correct expression (Figure 1). The presence 
and correct orientation of the vector were verified by 
PCR and automatic sequencing, respectively. The vec-
tor was kept in Escherichia coli Top Ten (Invitrogen) 
until use.
Bovine Primary Cell Line Transfection. A 
primary cell line was obtained from an ear biopsy of 
a 5-yr-old Jersey cow. The sample was processed as 
stated by Baldassarre et al. (2004).
For transfection, the culture medium from 70% 
confluent cells was replaced with Opti-MEM medium 
(Gibco). Resistant single colonies were isolated and 
expanded in the presence of 25 μg/mL of neomycin and 
then cryopreserved in liquid nitrogen. Cell lines were 
analyzed as previously described by Keefer et al. (2001) 
using fluorescent in situ hybridization (FISH) to con-
firm the presence of the entire vector and to determine 
the integration sites. Bovine transgenic cells (0.5 to 
1.3 × 105) were plated onto 24- or 96-well plates and 
cultured in Dulbecco’s modified Eagle medium (Gibco) 
supplemented with 15% fetal bovine serum (FBS) until 
they reached 100% confluence. After this, cells were 
cultured at 38°C, 5% CO2 in air in Dulbecco’s modified 
Eagle medium with 0.5% FBS, 20 mg/mL gentamicin, 
and 25 μg/mL neomycin for 4 d until the day of nuclear 
transfer.
Embryo Production by SCNT
Oocyte Maturation. Ovaries were collected at a 
local slaughterhouse and transported to the labora-
tory in sterile 0.9% NaCl solution at 20°C within 3 
h. Cumulus-oocyte complexes (COC) were recovered 
by aspiration of 2 to 10 mm follicles using a 21-gauge 
needle attached to a vacuum pump; only COC with 
more than 3 layers of compact and unexpanded cu-
mulus cells were selected and cultured, as described 
in Mucci et al. (2006). Between 40 and 50 COC were 
incubated in 400 μL of maturation medium at 38.5°C 
in 5% CO2 with maximum humidity. The maturation 
medium consisted of M199 (Gibco) supplemented with 
100 μM cysteamine, and 0.1 IU of recombinant human 
FSH (Gonal F75, EMD Serono, Rockland, MA) and 
10% FBS (Gibco).
Nuclear Transfer. All procedures were performed 
as described by Keefer et al. (2002) and Baldassarre 
et al. (2004), with minor modifications. After 18 h of 
maturation, the cumulus cells were removed by vortex-
ing for 1 to 2 min in HEPES synthetic oviductal fluid 
(H-SOF; 20 mM HEPES, 5 mM NaHCO3, 107.7 mM 
NaCl, 7.1 mM KCl, 1.2 mM KH2PO4, 1.5 mM MgSO4, 
7.3 mM sodium pyruvate, 0.2 mM l-glutamine, 1.8 mM 
citrate, 1.8 mM CaCl2∙2H2O, 5.4 mM sodium lactate, 
and 1% BSA) containing 1 mg/mL hyaluronidase. De-
nuded oocytes that presented polar bodies were washed 
and returned to the maturation medium in the incuba-
tor. The enucleation process was initiated within 30 
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min of oocyte denuding using an inverted microscope 
(Nikon Eclipse TE-300, Nikon, Tokyo, Japan) and mi-
cromanipulators (NT 88 V3, Nikon).
Oocytes were incubated for 10 min in H-SOF supple-
mented with 10 μg of Hoechst 33342 per milliliter at 
38°C, placed into manipulation drops (H-SOF supple-
mented with 1% FBS) covered with mineral oil, and 
finally enucleated after a brief exposure to UV light 
(Nikon Filter Set 01) to determine the location of 
DNA. Donor cells were collected from the culture plate 
by trypsinization using 0.05% trypsin-EDTA, washed 
twice, and finally resuspended in H-SOF. Cells were 
picked up with the transfer needle and slipped into the 
perivitelline space of enucleated oocytes. Cell-cytoplast 
couplets were fused immediately after cell transfer using 
a 0.5-mm gap fusion chamber (BTX, San Diego, CA) 
overlaid with sorbitol fusion medium (0.25 M sorbitol, 
0.5 mM magnesium acetate, 0.1% BSA) with a 25-μs 
pulse of 2.4 kV/cm (BTX Electrocell Manipulator 630, 
Harvard Apparatus, Holliston, MA). The postfusion 
culture medium consisted of H-SOF plus 5% FBS with 
5 mg/mL of cytochalasin B. After 1 h, fused couplets 
were activated with 5 mM ionomycin in H-SOF for 
4 min, and then 4 h of culture in 2 mM 6-dimethyl-
aminopurine at 38.5°C in 5% CO2 in air with maximum 
humidity. After this, presumptive embryos were rinsed 
in H-SOF and placed into 4-well plates with culture 
medium (SOF citrate) under mineral oil. Embryos were 
cultured for 7 d at 38.5°C in 5% CO2, 5% O2, 90% N2 
with maximum humidity (Sanyo MCO 175M, Morigu-
chi, Japan) until they were transferred to recipients.
Embryo Transfer and Pregnancy Detection. 
Three-year-old multiparous Aberdeen Angus cows were 
used as embryo recipients. Estrus was synchronized by 
the intramuscular application of 2 doses of 2 mL of 
PGF2α separated by 11 d. Embryos were transferred 7 
d after heat was detected. Pregnancies were confirmed 
by ultrasonography scanning using a transrectal 5-MHz 
linear array probe (Aloka 500, Hitachi-Aloka, Tokyo, 
Japan) 23 d after embryo transfer. Pregnant recipients 
were monthly evaluated by rectal palpation and ultra-
sonography scanning.
Birth and Neonatal Care
A neonatology unit was equipped to prevent or treat 
the most common pathologies associated with the birth 
of clones obtained by SCNT. Ten days before the es-
timated day of birth, the fetal position and viability 
were examined by rectal palpation. On the same day, 
birth was induced by intramuscular administration of 
30 mg of dexamethasone and 25 mg of PGF2α. In cases 
Figure 1. Schematic presentation of the vector used to transfect NMuMG and Jersey cow cells. The pIRES2-EGFP vector (Clontech Inc., 
Mountain View, CA) was used as backbone. Cytomegalovirus promoter was replaced by the goat β-CN promoter obtained from the pBC-1 milk 
expression system (Invitrogen, Carlsbad, CA). Kozak sequences were added to each cDNA (human lactoferrin and lysozyme). SV40 = simian 
virus 40 origin of replication; Kan/Neo = kanamycin/neomycin; HSV KY Poly A = polyadenylation signal herpes simplex virus thymidin kinase 
gene; pUCori = pUC vector origin of polyadenation signal of simian virus 40; IRES = international ribosome entry site.
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in which no signs of parturition were observed, 36 h 
after induction obstetric maneuvers were performed 
to evaluate the fetal position and response to stimuli. 
When necessary, a cesarean section was performed in 
a standing position through a left flank approach for 
the recovery of fetuses. Immediately after delivery the 
calf was transferred to the neonatology unit to assess 
its physiological status and receive the first veterinary 
care.
Genotyping of Cloned Animals
To corroborate that the born animal shared the 
genotype of the transfected cells, a genotyping test for 
bovines was performed (StockMarks for Cattle Bovine 
Genotyping Kit, Applied Biosystems, Thermo Fisher 
Scientific, Waltham, MA). The test was based on the 
detection of 11 microsatellites and performed in an 
automatic genetic analyzer (ABI Prism 3730, Applied 
Biosystems). Markers were authorized by the Inter-
national Society of Animal Genetics and the results 
processed with Data Collection and Gene Mapper v0.4 
software (Applied Biosystems).
FISH
To determine the integration site and the number 
of insertions of the vector, FISH was performed using 
the expression vector as probe. Briefly, 10 μg of the 
vector was digested with DNase I, and a nick transla-
tion reaction with Escherichia coli polymerase I using 
deoxycytidine-5′-triphosphate (dCTP)-Rhodamine-
labeled nucleotides was performed.
Skin samples were obtained from the presumptive 
transgenic calf and processed as previously described. 
Once obtained, cells were cultured in the presence of 
50 μg/mL of colchicine (Colcemid, Gibco) for 4 h, re-
suspended, and washed with hypotonic solution (0.05 
M KCl in water). Mounting was performed by directly 
dropping cells onto a slide before fixation with Carnoy 
solution (3:1 methanol:acetic acid). The insert was vi-
sualized at 400× in an Eclipse 2000 microscope (Nikon) 
by using rhodamine and DAPI (4′,6-diamidino-2-phe-
nylindole; DNA staining) filters to contrast with the 
red positive potential signals of the hybridized probe.
Induction of Artificial Lactation
The calf that was born was kept in a pen under con-
trolled growing conditions, which included a complete 
sanitary plan and feeding schedule until lactation. 
To obtain milk from the calf before its physiological 
lactation, an artificial induction was performed. The 
1-yr-old calf was treated following the protocol sug-
gested by a field veterinary. Treatment consists of a 
daily intramuscular dose of 20 mg of estradiol cypio-
nate (Konig, Buenos Aires, Argentina) from d 1 to 14. 
On d 1, a progesterone injection of 125 mg (Syntex, 
Buenos Aires, Argentina) and the introduction of an 
intravaginal device of 1 g of progestogen (Syntex) was 
performed. The device was replaced by a new one on 
d 4 and removed on d 7, when another progesterone 
injection was given (5 mL). On d 15 and 16, 25 μg of 
PGF2α (Syntex) was administered, followed by 20 mg 
of dexamethasone at d 18, 19, and 20 of treatment. 
On d 21, 3 mL of Orastine (Intervet, Buenos Aires, 
Argentina) was administered and manual milking 
started. Milking was performed for 57 d twice a day 
(morning and evening) and then ceased. Samples were 
fractioned and frozen at −20 and −80°C. Colostrum 
from second day and milk from d 35 were used for 
protein analysis.
Lyophilization of Colostrum and Milk Samples
Fluid raw colostrum and milk samples (200 mL) were 
placed in the lyophilizer VirTis Benchtop 6K (VirTis, 
SP Scientific, Warminster, PA) in 50-mL tubes (Falcon, 
Carlsbad, CA). The drying process was conducted for 
12 h using a vacuum lyophilizer and cooling to −5°C. 
Freeze-dried colostrum and milk were stored in a poly-
ethylene bag with zipper until use.
Detection and Quantification of Human  
Proteins in Milk
Specific Antibodies Against Human Lactofer-
rin. Lactoferrin was purified from human milk by cat-
ion exchange chromatography using am SP-Sepharose 
column, and polyclonal antiserum against human lac-
toferrin (hLF) was obtained in rabbits as described 
previously using the purified protein (Conesa et al., 
2008). To eliminate the antibodies that gave cross-
reactivity with bovine lactoferrin (bLF) from the anti-
hLF antiserum, the polyclonal antiserum was passed 
through an immunoaffinity column with insolubilized 
bLF (donated by Tatua Nutritionals Company, Mor-
rinsville, New Zealand). To eliminate cross-reactivity 
with bLF, the antiserum anti-hLF was added to the 
gel with insolubilized bLF. The mixture was incubated 
for 1 h with gentle agitation at room temperature and 
afterward mounted into a column. The antibodies that 
did not react with bLF eluted with 25 mM phosphate 
potassium buffer, 0.5 M NaCl, pH 7.4, and were stored 
for further isolation of specific antibodies against hLF. 
An immunoaffinity column (similar to the one for bLF) 
with insolubilized hLF was used to obtain specific 
antibodies against hLF. The more strongly retained 
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antibodies were eluted with the buffer described above 
added with 10% of dioxane.
Immunodotting Technique. The elimination of 
cross-reactivity of the antiserum anti-hLF with bLF 
and the presence of hLF in bitransgenic milk and colos-
trum were verified by immunodotting. The samples (1 
μL) were applied onto a nitrocellulose membrane with 
a pore size of 0.45 μm and left to dry. The membrane 
was then saturated with 5% ovalbumin (wt/vol) in 2 
mM potassium phosphate, 8 mM sodium phosphate, 3 
mM KCl, 0.14 M NaCl, pH 7.4 (PBS) by incubation for 
1 h at room temperature. After 5 washes with PBS, the 
membrane was incubated with antiserum monospecific 
against hLF, diluted 1:50 in PBS with 3% ovalbumin 
for 1 h. The membrane was washed again 5 times with 
PBS and incubated with goat anti-rabbit IgG antibod-
ies conjugated with peroxidase and diluted 1:1,000 in 
PBS with 3% ovalbumin. Finally, after 5 washes, the 
membrane was revealed with a solution of peroxidase 
substrate prepared as follows: 3 mg of 4-chloro-1-naph-
thol, 1 mL of methanol, 4 mL of 10 mM potassium 
phosphate, 0.15 M NaCl (pH 7.4), and 5 μL of H2O2. 
The reaction was stopped by washing the membrane 
with distilled water. At the point of sample application, 
a greyish coloration was observed when a positive reac-
tion with the antibodies occurred.
Western Blot. Colostrum and milk samples from 
the transgenic heifer, human (positive control), and 
cow (negative control, raw milk obtained from pooled 
dairy farm cows) were tested for the presence of hLF 
and human lysozyme. The samples (100 μL) were 
mixed with cracking buffer [50 mM Tris-HCl (pH 6.8), 
100 mM dithiothreitol, 2% SDS, 0.1% bromophenol 
blue, and 10% glycerol]. The samples were resolved 
in SDS-PAGE, 12% polyacrylamide gel (acrylamide/
bisacrylamide, 19:1), and separated at 200 mA for 2 h 
in running buffer (25 mM Tris, 250 mM glycine, and 
0.1% SDS). Proteins were transferred to a nitrocellulose 
membrane (Millipore, Billerica, MA) by using a Mini 
subcell chamber (Bio-Rad, Hercules, CA) set up at 25 
mA for 2 h. The membrane was washed and blocked for 
1 h with Tris-buffered saline (TBS; 50 mM Tris-HCl 
pH 7.6 and 150 mM NaCl) with 5% cold fish gelatin 
and 2% normal horse serum. The membranes were 
incubated with commercial monoclonal antibodies for 
human lactoferrin (Abcam, Cambridge, UK) or human 
lysozyme (Abcam), both generated in rabbit. After sev-
eral washings with buffer, a goat anti-rabbit antibody 
marked IRD 800CW IgG (Li-Cor, Lincoln, NE) was 
used as secondary antibody diluted 1:20,000 in TBS 
3% cold fish gelatin solution for 1 h. Washings with 
TBS 0.1% Tween 20 were done and signal detection 
performed by an Odyssey Quantitative Fluorescence 
Imaging System (Li-Cor).
Development of an ELISA to Quantify hLF. 
This technique was developed to quantify the con-
centration of hLF in bitransgenic milk samples that 
were provided in powder (obtained by conventional 
lyophilization of the whole secretion) and reconstituted 
with distilled water to the original volume. The wells 
of Maxisorp strips (provided by Nunc, Thermo Fisher 
Scientific) were coated with 100 μL per well of anti-hLF 
antibodies at 5 μg/mL, dissolved in 0.05 M sodium car-
bonate buffer, pH 9.6, and kept overnight at 4°C. The 
wells were washed 5 times with PBS with 0.05% Tween 
20 in an automatic washer. Then, wells were incubated 
with 300 μL of 3% ovalbumin in PBS for 2 h at 37°C. 
Afterward, they were washed 5 times and incubated 
with 100 μL of hLF standards (0, 10, 25, 50, 100, 250, 
500, and 1,000 ng/mL) and bitransgenic milk samples 
for 1 h at 37°C. After 5 washings, the wells were incu-
bated with 100 μL of anti-hLF antibodies conjugated 
with horseradish peroxidase according to Catty and 
Raykundalia (1989; dilution 1:5,000 in PBS with 1% 
ovoalbumin). Finally, the wells were washed 5 times 
and incubated with 100 μL of peroxidase substrate 
consisting of 3,3′,5,5′-tetramethylbenzidine (Zeulab, 
Zaragoza, Spain) for 30 min at room temperature. The 
reaction was stopped by adding 50 μL of 2 M sulfuric 
acid, and the absorbance at 450 nm was measured in 
a plate reader Multiskan MS (Labsystem, Helsinki, 
Finland). The ELISA was validated as described in 
the Supplemental Material (https://doi.org/10.3168/
jds.2016-11173).
Isolation of Lysozyme from Human Milk. 
Human lysozyme was isolated from the fractions cor-
responding to the excluded volume obtained in the 
isolation of hLF by cation exchange chromatography. 
Those fractions were pooled, concentrated 10 times by 
UF and subjected to Sephadex G-50 (ø 1 × 65.5 cm) 
chromatography. The elution was carried out with PBS 
containing 1 M NaCl at a flow rate of 1 mL/min and 
collecting 2-mL fractions. The purity of the protein was 
assessed by SDS-PAGE in Phast System equipment 
(GE Healthcare Life Sciences, Pittsburgh, PA).
Competitive ELISA to Quantify Human Ly-
sozyme. The content of lysozyme in bitransgenic 
milk and colostrum was determined by the Lysozyme 
Human ELISA kit of Abcam. The 96-well plate was 
supplied coated with specific lysozyme antibodies. 
The standards (3, 1.5, 0.750, 0.375, 0.188, 0.094, and 
0.047 μg/mL) or samples were added in a volume of 
25 μL per well and immediately 25 μL of biotinylated 
lysozyme was added on top. The plate was incubated 
for 2 h at room temperature and, afterward, the wells 
were washed 5 times with washing buffer and incubated 
with 50 μL of streptavidin-peroxidase conjugate for 30 
min. The wells were washed 5 times and the chromogen 
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substrate was added per well and incubated 10 min or 
until the optimal color developed. Finally, 50 μL of stop 
solution was added per well and the absorbance was 
determined at 450 nm.
Determination of Enzymatic Activity of Lyso-
zyme in Milk Secretions. The activity of lysozyme 
was determined by a turbidimetric method, measuring 
the decrease in absorbance at 450 nm of a fresh suspen-
sion of Micrococcus lysodeikticus versus time. For this 
purpose, 8 mg of this bacterium was suspended in 25 
mL of 100 mM potassium phosphate buffer, pH 6.2. A 
volume of 950 μL of the bacterial suspension was placed 
in a glass cuvette, adding 50 μL of the sample in which 
lysozyme activity had to be determined. The decrease 
in absorbance was measured continuously at 450 nm. 
The enzymatic activity was determined from the slope 
of the curve obtained by representing the absorbance 
versus time.
Detection of Casein and Whey Proteins
Casein and milk serum proteins were detected by 
reverse-phase HPLC (ISO, 2004). The area of each 
peak in the chromatogram obtained was relativized to 
total casein and concentration for each casein expressed 
as a percentage.
RESULTS
Embryo Production and Transfer
Two SCNT procedures were performed using the 
bitransgenic cell lines. In the first, we obtained single 
Day-7 embryos from 27 reconstructions (62% fusion 
rate). The embryo was transferred to a recipient and 
resulted in a 30-d pregnancy. The recipient was sent to 
a local slaughterhouse to recover the fetus for studies. 
Transgenesis was confirmed by FISH of the primary 
cell culture from the fetus (data not shown).
The second nuclear transfer procedure was performed 
with the same transgenic cell batch, from which we 
obtained 8 Day-7 transferable embryos from 54 recon-
structions after SCNT (69% fusion rate). Six embryos 
were transferred to previously synchronized recipients, 
4 single transfers with embryos rated 1 to 2 (according 
to International Embryo Technology Society ratings; 
www.iets.org) and 2 double transfers with embryo qual-
ity 3. Two cows were detected pregnant (1 single and 1 
double) on d 30 (pregnancy rate: 33% per transferred 
recipient, 37.5% per transferred embryo).
Birth and Neonatal Care
Thirty hours after birth induction, fetal viability 
of the double pregnancy was compromised and, after 
a cesarean section, 2 dead Jersey female fetuses were 
recovered. No evident pathologies were found during 
fetal necropsy. Each fetus weighed 21 and 16 kg, respec-
tively. Placentas presented fewer than 30 placentomes 
each, the larger ones 15 cm in diameter. Tissue samples 
were sent to the pathology laboratory (INTA, Balcarce, 
Argentina), resulting in mild pericarditis and inter-
stitial pneumonia in one fetus and hemorrhage in the 
central nervous system in the other fetus. One placenta 
presented mild lymphocytic placentitis.
The remaining pregnant cow gave birth by a cesarean 
section to a female Jersey calf that weighed 45 kg. The 
calf received 25 mg of doxapram (Viviram, Holliday, 
Argentina) and an antimicrobial rational preventive 
therapy immediately after birth. The calf was kept in 
the neonatal unit until d 80, receiving specific therapies 
in case of need. On d 81, the calf started a normal life 
following normal feeding and health care protocols.
Genotyping and FISH
Genotyping results from the born calf, cell line, 
and Jersey cow from which the tissue sample was 
taken (founder) shared the same microsatellite markers 
(data not shown). To verify the presence of the vector 
(pIRES/LF/lyso) in the calf genome and to determine 
the number of insertions and the target chromosomes, 
a FISH was performed. A clear sign of the vector was 
found as a single copy in chromosome 7 (Figure 2).
Figure 2. Fluorescent microscopic image (400×) of the vector 
insertion (arrow). The probe was labeled with Rhodamine (Sigma-
Aldrich, St. Louis, MO), and DAPI (4′,6-diamidino-2-phenylindole, 
Sigma-Aldrich) was used to stain DNA.
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Lactation
The treatment to induce lactation started when the 
calf was 13 mo old. The calf started producing 400 mL 
of milk per day and reached 6 L per day on d 60, when 
milking stopped. The teats were then sealed with a 
commercial product (Bovigam R, Bayer, Buenos Aires, 
Argentina).
Specific Antibodies Anti-Human Lactoferrin  
and Immunodotting
Immunodotting results are shown in Figure 3. No 
cross-reactivity with bLF was detected, and the pres-
ence of hLF in bitransgenic milk and colostrum was 
confirmed by the positive reaction of specific antibod-
ies with both samples. A positive reaction in the posi-
tion corresponding to human milk was also observed, 
whereas we observed no reaction in the position cor-
responding to bovine milk.
Western Blot for the Detection of hLF  
and Human Lysozyme
We found a clear positive sign of the presence of 
both human proteins in the bitransgenic cow milk us-
ing monoclonal antibodies against hLF (Figure 4) and 
human lysozyme (Figure 5) in the milk and colostrum 
Figure 3. Immunodotting to test the specificity of antibodies 
against human lactoferrin (hLF) in which the nitrocellulose mem-
branes were incubated with a polyclonal antiserum against hLF di-
luted 1:50 (A) and with specific antibodies anti-hLF after elimina-
tion of cross-reactivity with bovine lactoferrin (bLF) diluted 1:50 (B). 
Samples: 1 = hLF (1 mg/mL); 2 = bLF (1 mg/mL); 3 = hLF + bLF 
(0.5 mg/L + 0.5 mg/L); 4 = whey of bitransgenic colostrum; 5 = whey 
of bitransgenic milk; 6 = BSA (1 mg/mL); 7 = human milk; 8 = hu-
man α-LA; 9 = bovine milk.
Figure 4. Expression of human lactoferring (hLF) in the bitrans-
genic cow’s mammary gland. Western blot was performed and samples 
were detected with specific antibodies for hLF. M = molecular marker; 
H = human milk; B = pooled milk from dairy cows; Tm = milk from 
a bitransgenic cow (10 d after milking started); Tc = colostrum from 
bitransgenic cow (1 d after milking started).
Figure 5. Expression of human lysozyme (hLZ) in bitransgenic 
cow. Western blot was performed and samples were detected with spe-
cific antibodies for hLZ. M = molecular marker; H = human milk; B 
= pooled milk from dairy cows; Tm = milk from bitransgenic cow (10 
d after milking started); Tc = colostrum from bitransgenic cow (1 d 
after milking started).
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of the bitransgenic cow, which coincided with the ex-
pected molecular weights. The positive control (human 
milk) revealed a band according to the protein mo-
lecular weight, whereas the negative control (cow milk) 
gave no sign.
Quantification of hLF and Human Lysozyme
Human protein concentrations in the calf colostrum 
and milk were assessed by ELISA. Human lactoferrin 
concentration was 0.0098 mg/mL in cow colostrum 
and 0.011 mg/mL in milk, whereas human lysozyme 
concentration was 0.0022 mg/mL in cow colostrum 
and 0.0024 mg/mL in milk. Considering the molecular 
weight of each protein (80 and 16.5 kDa for hLF and 
human lysozyme, respectively), the transformation to 
molar concentration shows that hLF is present in cow 
milk at 139.74 nM (8.31 × 1013 molecules/mL) and that 
human lysozyme is present at 145.45 nM (8.75 × 1013 
molecules/mL).
Enzymatic Activity of Lysozyme
The enzymatic activity of lysozyme was determined 
by the turbidimetric method and the results are shown 
in Table 1. The sample with the highest activity against 
M. lysodeikticus was the recombinant human lysozyme 
from rice (donated by Ventria Bioscience, Sacramento, 
CA), which was used as reference, followed by lysozyme 
isolated from human whey. It is necessary to note that 
enzymatic activity was measured in pure isolated lyso-
zymes from recombinant rice and human whey, which 
were used as references, whereas the values of activity 
for the other samples were measured directly in milk or 
colostrum secretions without isolating previously the 
enzymes. With regard to bitransgenic milk samples, the 
highest enzymatic activity was measured in colostrum.
Casein and Whey Protein Concentration
Total casein concentration, determined by HPLC in 
the milk of the bitransgenic cow, was 41.5 g/L, whereas 
that in colostrum was 72 g/L. Among total casein, 
α-CN represented 51.2 (21.25 g/L) and 64.8% (46.65 
g/L) and β-CN represented 48.8 (20.25 g/L) and 35.2% 
(25.35 g/L), respectively; κ-CN was found in trace 
amounts. The α-LA concentration was 2.4 g/L in milk 
and 1.8 g/L in colostrum, whereas β-LG concentration 
was 6.4 and 8.4 g/L, respectively.
DISCUSSION
The mammary gland is one of the readily available 
animal bioreactors, and by the use of recombinant 
protein technologies it can be directed to produce 
pharmaceuticals and add beneficial molecules for hu-
man health to the milk. Expression vector construction 
for transgenic expression of recombinant proteins still 
needs to be optimized (Houdebine, 2009). One strategy 
for optimization includes using elements such as insula-
tors and matrix-attached regions, but the expression 
level of proteins is still often low. For these reasons, 
construction of the targeting vector is one of the most 
important goals for mammary gland bioreactors, but 
currently available techniques are laborious, time-con-
suming, and inefficient (Yu et al., 2012). One approach 
to enhance protein production is to introduce several 
copies of the same gene under the effect of a single 
promoter, by using bi- or polycistronic vectors. We 
obtained the first bicistronic cow expressing hLF and 
human lysozyme by using a modified IRES-containing 
vector. The principal use of IRES-containing plasmids 
was the simultaneous expression of 2 independent cis-
trons for the co-transfection of a marker gene with the 
gene of interest. Vectors containing resistance genes 
(e.g., to neomycin, hygromycin), in addition to the 
gene of interest, have been constructed (Gurtu et al., 
1996; Rees et al., 1996; Veelken et al., 1996; Hobbs et 
al., 1998) and demonstrated to be useful in establish-
ing stable cell lines expressing a gene of interest. We 
found that the 2 transgenic proteins obtained from the 
bitransgenic cow had a similar molar concentration in 
colostrum and milk. However, Mizuguchi et al. (2000) 
reported the differential expression of a second gene 
while using IRES co-expression in several cultured cell 
lines and in mouse liver in vivo. The expression of the 
IRES-dependent second gene ranged from 6 to 100% (in 
most cases between 20 and 50%) compared with the first 
gene’s expression. Analysis of transgenic animals result-
ing from microinjection of IRES constructs showed that 
expression levels of both genes vary and are generally 
lower than those of the same genes transcribed indi-
vidually (Jankowsky et al., 2001); this is likely because 
polycistronic mRNA are unusual for higher eukaryotic 
cells and mechanisms preventing their normal function 
Table 1. Enzymatic activity of lysozyme in samples from different 
origin, estimated by the decrease in absorbance at 450 nm (ΔAbs 450) 




Rice recombinant human lysozyme (1 mg/mL) 230





1The values represent the mean of values corresponding to 3 indepen-
dent experiments.
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are triggered. Similarly, transgenic animals contain-
ing more than 2 genes have been obtained by using 
sperm-mediated gene transfer (Webster et al., 2005), 
resulting in 7 triple transgenic, 7 double transgenic, 
and 4 single transgenic piglets for fluorescent proteins. 
Deng et al. (2011) used a 2A peptide approach and 
obtained 11 multitransgenic piglets, 7 of which co-
expressed 4 fluorescent proteins at equivalently high 
levels and 4 of which showed slight discrepancies in 
protein expression. These results were achieved with 
vectors constructed with no more than 2 genes under 
the control of a promoter. When 4 genes were driven 
by a single cytosine-adenine-guanine (CAG) promoter 
it was not efficient enough to mediate the co-expression 
of the 4 genes in the primary fetal fibroblast cell line 
and the embryos obtained. The expression of the last 
2 genes was much weaker than that of the first 2 genes 
in the polycistronic cassette, suggesting that the cleav-
age efficiencies at the downstream 2A sites were lower 
than those at the upstream 2A sites. In our experiment, 
only 2 proteins were included in the vector; thus, the 
functionality of the vector for more than 2 genes should 
be assessed in the future.
Different promoters, including αS1-CN, β-CN, β-LG, 
α-LA, and hybrid promoters, which coincide with 
the proteins that account for approximately 90% of 
all proteins in bovine milk (Ikonen et al., 1999), have 
been used for the specific expression of recombinant 
proteins in milk (Yuan et al., 2014). We used a β-CN 
gene promoter, which is one of the most efficient and 
most commonly used in the mammary glands of mice, 
goats, and cows (for review, see Maksimenko et al., 
2013). Because the length of the β-CN promoter can be 
optimized for efficient recombinant protein expression 
from 950 bp (Ahn et al., 1995) to 10 kb (Sohn et al., 
2003), we used a 4,112-kb promoter. Casein promoters 
possess binding sites for transcription factors, including 
activators of transcription, enhancer binding proteins, 
and glucocorticoid receptors (Raught et al., 1995; Buser 
et al., 2007), and expression of milk protein genes are 
regulated by interactions between particular hormone-
activated transcription factors during mammary gland 
development. Western blot results demonstrated that 
the recombinant proteins were expressed in milk and 
colostrum, both of the expected size. A novel approach 
of using a hybrid promoter or enhancer has been re-
ported to increase specific expression of hLF in the 
mouse mammary gland (Cheng et al., 2012), although 
inherent regulatory sequences of different species and 
the differences of the protein genes are the main sub-
jects to be taken into account to optimize transgenic 
protein production (Yuan et al., 2014).
After artificial induction, milk production was simi-
lar to that observed by Jewell (2002), who found more 
than 5 kg/d of milk yield in 80% of induced Jersey 
heifers. The concentration of total protein in the bi-
transgenic calf milk was high (47.3 g/L), whereas 
Jewell (2002) found an average concentration of 38 
g/L, higher than that observed in noninduced Jersey 
cows (33 g/L). Similarly, Sawyer et al. (1986) reported 
that percentages of protein and fat were higher in milk 
from lactation-induced heifers than in milk from heifers 
after normal calving for the first 14 d. In the present 
study, increased protein concentration did not alter 
the proportion of 80% caseins to 20% whey proteins. 
An increase in β-CN (almost 50% of the caseins) was 
observed in milk, whereas the other major casein (i.e., 
α-CN) remained at normal concentrations (21–25 
g/L). Likewise, whey proteins were increased, and the 
expected α-LA + β-LG concentration of 8.8 g/L was 
obtained in the milk of the transgenic calf.
In bovine milk, lactoferrin is in its highest levels in 
the first 2 d of lactation and then decreases very mark-
edly (Sánchez et al., 1988); however, the milk secretions 
obtained in our study do not seem to have the same 
evolution. It has to be considered that the lactation 
of the bitransgenic calf was hormone-induced; there-
fore, the pattern of protein secretion might be altered 
respect to a natural lactation, as described in previ-
ous studies (Jewell, 2002). Similar concentrations of 
both lactoferrin and lysozyme have been obtained in 
colostrum compared with milk, perhaps due to the use 
of the β-CN promoter, a protein that has been found 
in similar amounts or slightly reduced in colostrum 
compared with milk (Ontsouka et al., 2003), marking 
no effect of the lactation period on the casein family 
promoters.
The concentration of hLF obtained in the present 
study was similar to that found by Neville and Zhang 
(2000), who reported 0.01 to 0.03 mg/mL during bo-
vine lactation. The first recombinant human lactoferrin 
(rhLF) bull was produced by the Pharming Group 
NV (Leiden, the Netherlands) in 1990 (Krimpenfort 
et al., 1991) by microinjection, and the hLF gene was 
under the control of the bovine αS1-CN promoter. van 
Berkel et al. (2002) obtained 0.8 mg/mL of lactoferrin 
in a transgenic cow in 2002 using the same technique 
and promoter; those authors also obtained 3 male 
transgenic individuals, whose F1 daughters produced 
between 0.3 and 2.3 mg/mL of lactoferrin. The rhLF 
of the transgenic cows and natural hLF show similar 
structural and functional properties in vitro (Thomas-
sen et al., 2005) and have been reported as structur-
ally and functionally similar, as the homology of hLF 
and bLF at the protein level is 69% (Nuijens et al., 
2009). Hyvönen et al. (2006) obtained a basic mean 
concentration of rhLF in the milk of transgenic cows of 
2.9 mg/mL during early lactation, and a concentration 
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of bLF of 0.07 mg/mL. These cows were produced by 
multiple ovulation and embryo transfer using semen 
from a transgenic bull obtained by pronuclear injection. 
Yang et al. (2008) obtained 2 transgenic calves by using 
microinjection of bacterial artificial chromosome DNA 
containing the entire genomic sequence of hLF. Two 
copies were inserted in one calf and one in the other. 
Analysis by RIA further demonstrated that rhLF was 
highly expressed in the transgenic milk, at concentra-
tions of 2.560 and 3.460 mg/mL. Recombinant hLF was 
also obtained from transgenic goats, for which the lev-
els of hLF achieved were of 0.765 mg/mL (Zhang et al., 
2008), and transgenic rabbits, with levels of 0.103 mg/
mL (Li et al., 2006). However, in transgenic mice, hLF 
levels obtained were low, between 0.001 and 0.036 mg/
mL (Platenburg et al., 1994). Regarding recombinant 
human lysozyme, Yang et al. (2011) reported that the 
expression level of this protein in milk was between 
0.013 and 0.02596 mg/mL, as measured by RIA by us-
ing a bovine β-CN promoter and different kinds of fetal 
cells. Recombinant human lysozyme has also been ex-
pressed in other mammals, such as goats (Maga et al., 
2006), obtaining higher levels than in or study (0.270 
mg/mL). Although the level of human lysozyme is low 
in the bitransgenic milk and colostrum of our study, 
its enzymatic activity is comparable to that of human 
milk. Furthermore, the lysozyme activity found for the 
bitransgenic milk would correspond mainly to that of 
human recombinant lysozyme, as we found very low 
levels of lysozyme activity at the same conditions and 
to previous reports (Benkerroum, 2008).
Low levels of transgenic proteins could be explained 
by the insertion of the foreign DNA into a gene-poor re-
gion, characterized by frequent DNA breaks (Goldman 
et al., 2004). The chromatin in these regions typically 
exert a negative influence on the expression of the trans-
gene integrated nearby. Several regulatory elements are 
used to protect the transgene expression, which in our 
case was excluded from the fragments of the pBC1 vec-
tor used for the construction to achieve a smaller vector 
size. For the same reason, we used cDNA instead of 
the complete DNA sequence of the human genes. The 
use of introned or partly introned genes is preferable 
due to the presence of regulatory sequences, enhanced 
stability of the primary transcripts, and increased 
transgene expression efficiency (Whitelaw et al., 1991; 
Hennighausen, 1992). Bacterial artificial chromosome 
generally contain all the regulatory elements neces-
sary for gene expression (Giraldo and Montoliu, 2001), 
probably diminishing the position effect caused by the 
chromosomal insertion site of an exogenous gene.
Although most milk parameters were not analyzed 
in our work, Zhang et al. (2012) demonstrated that the 
parameters measured in milk from transgenic cloned 
cattle (almost 70 proteins) were all within the normal 
range compared with control milk. The authors (Zhang 
et al., 2012) used 3 different transgenic cell lines to 
obtain cows expressing approximately 0.01 mg/mL of 
lysozyme, 3.5 mg/mL of lactoferrin, and 1.5 mg/mL of 
α-LA.
We suggest that using the IRES approach and DNA 
editing techniques (such as CRISPR, clustered regular-
ly interspaced short palindromic repeats) for targeted 
recombination could enhance protein production, by 
using native promoters and active genome zones and 
maintaining the physiological expression patterns for 
the transgenic proteins. In summary, a bitransgenic cow 
expressing 2 human proteins in the mammary gland 
was produced by using an IRES-containing vector and 
the SCNT technique. This study demonstrates that 
transgenic animals producing more than one protein 
of interest in bovine milk can be efficiently obtained by 
using a single round of transfections and less antibiotic-
resistance markers, allowing the use of dairy herds as a 
source of high-quality nutraceutical or pharmaceutical 
proteins.
CONCLUSIONS
The presence of hLF and human lysozyme has been 
detected in the milk of the first bitransgenic cow in the 
world expressing 2 proteins of interest. This achieve-
ment is very important as a key step in the process of 
designing humanized milk with added biological value 
for newborn nutrition and development. The fact that 
the 2 proteins expressed in the bitransgenic milk have 
antibacterial activity and constitute the nonspecific 
defensive system of milk is of great relevance. Although 
the levels of hLF and human lysozyme in the bitrans-
genic milk and colostrum are low, the success in the 
generation of this bitransgenic cow is very promising 
because it could provide great benefits to human nutri-
tion and health in the near future.
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